GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
F

Fusion Antibodies FAB.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

5.00p

-4.76%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Fusion Antibodies

Its shares trade on LSE under the ticker FAB.L. It has been listed since 18 December 2017. In the fiscal year to 31 March 2026, it reported revenue of £2.1m and a net loss of £1.1m. At that date it held total assets of £2.7m and shareholders' equity of £1.6m.

Fusion Antibodies Plc engages in the provision of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The company is headquartered in Belfast, Northern Ireland. The company went IPO on 2017-12-18. The firm develops and commercializes antibody-based therapeutics for cancer. The firm develops a range of antibody engineering services based around monoclonal antibodies. The company focuses in the expression and purification of recombinant proteins and chimeric antibodies for the research, diagnostic and therapeutic markets. Its technology generates target specific antibodies from protein antigens. The firm's therapeutic and diagnostic research and development are offered as a service to pharmaceutical, biopharmaceutical and academic researchers.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Life Sciences Tools & Services
Listed since
18 Dec 2017
Employees
47

Leadership

Pay as last reported

  • Dr. Simon DouglasNon-Executive Chairman of the Board, since 2011£18,000
  • Dr. Adrian KinkaidChief Executive Officer, Executive Director, since 2022£179,000
  • Mr. Stephen SmythInterim Chief Financial Officer and Company Secretary, Executive Director, since 2023
  • Dr. Richard BuickChief Scientific Officer, Executive Director, since 2011£122,000
  • Mr. Colin WalshNon-Executive Director£27,000
  • Dr. Matthew BakerNon-Executive Independent Director£21,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Fusion Antibodies PLC has several strengths that give the company a competitive advantage:

Weaknesses

  • Despite its strengths, Fusion Antibodies PLC also faces some weaknesses:

Opportunities

  • Fusion Antibodies PLC has several opportunities to capitalize on:

Threats

  • Fusion Antibodies PLC faces various threats that could impact its business:

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.